Author

J. Vernerey

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. Goubard· 1 shared A. Iwama· 1 shared A. Krug· 1 shared A. Mazuel· 1 shared C. Costa Da Silva· 1 shared D. Birnbaum· 1 shared D. Olive· 1 shared E. Duprez· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Goubard

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single-cell multi-omics analyses reveal EZH2 as a main driver of retinoic acid resistance in PLZF-RARA leukemia.

M. Poplineau, N. Platet, A. Mazuel, L. Herault, S. Koide, W. Kuribayashi, N. Carbuccia, L. N'Guyen, J. Vernerey, M. Oshima, D. Birnbaum, A. Iwama, E. Duprez

This study identifies EZH2 as a driver of retinoic acid resistance in PLZF-RARA leukemia using single-cell multi-omics analyses and shows targeting pan-EZH2 activities can eliminate resistant cells.

bioRxiv · Jan 4, 2022 · PreprintCancer Biology

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

P.-L. Bernard, R. Delconte, S. Pastor, V. Laletin, C. Costa Da Silva, A. Goubard, E. Josselin, R. Castellano, A. Krug, J. Vernerey, R. Devillier, D. Olive, E. Verhoeyen, E. Vivier, N. Huntington, , G. Guittard

This study shows that deleting CISH enhances NK cell activation and anti-tumor responses in both mice and human cells, suggesting CISH as a therapeutic target for improving NK cell immunotherapy.

bioRxiv · Mar 16, 2021Immunology